Drug rechallenge following drug-induced liver injury.
Christine M HuntJulie I PapayVid StanulovicArie RegevPublished in: Hepatology (Baltimore, Md.) (2017)
For critical medicines, drug rechallenge may be appropriate when 1) no safer alternatives are available, 2) the objective benefit exceeds the risk, and 3) patients are fully informed and consent, can adhere to follow-up, and alert providers to hepatitis symptoms. To better understand rechallenge outcomes and identify key risk factors for positive rechallenge, additional data are needed from controlled clinical trials, prospective registries, and large health care databases. (Hepatology 2017;66:646-654).
Keyphrases
- healthcare
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- adverse drug
- peritoneal dialysis
- emergency department
- prognostic factors
- electronic health record
- drug induced
- type diabetes
- randomized controlled trial
- depressive symptoms
- patient reported outcomes
- metabolic syndrome
- patient reported
- artificial intelligence
- study protocol
- glycemic control
- phase iii